COVID-19 prophylaxis (excluding children) meta-analysis

• suggested 91 % decrease in 6 months symptomatic COVID with a moderate degree of certainty due to some concern in risk of bias
• suggested 82 % decrease in confirmed Covid-19, from 1st dose with a moderate degree of certainty due to some concern in risk of bias
• suggested 82 % decrease in vaccine efficacy from randomization (ITT) with a moderate degree of certainty due to some concern in risk of bias
• demonstrated 95 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 3.9-fold increase in related AE (TRAE) with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 1.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 74 % increase in severe adverse events with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 9.7-fold increase in lymphadenopathy, any with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 2.7-fold increase in musculoskeletal and connective tissue disorders, any with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 23.9-fold increase in local adverse reaction, any, dose 1 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 22.0-fold increase in local adverse reaction, any, dose 2 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 63 % increase in systemic adverse reaction, any, dose 1 with a moderate degree of certainty due to some concern in risk of bias
• statistically significant 3.6-fold increase in systemic adverse reaction, any, dose 2 with a moderate degree of certainty due to some concern in risk of bias

• suggested 87 % decrease in hospitalization
• suggested 94 % decrease in symptomatic Covid-19

• statistically significant 24 % increase in intracranial hemorrhage

• statistically significant 22 % increase in paresthesia

• suggested 97 % decrease in symptomatic Covid-19

• statistically significant 43 % increase in herpes zoster infection but with a very low degree of certainty due to critical risk of bias
• statistically significant 2.2-fold increase in myocarditis but with a very low degree of certainty due to critical risk of bias
• statistically significant 40 % increase in appendicitis but with a very low degree of certainty due to critical risk of bias
• statistically significant 1.4-fold increase in lymphadenopathy, any but with a very low degree of certainty due to critical risk of bias

• suggested 61 % decrease in confirmed COVID (any severity)

• suggested 86 % decrease in infection (PCR positive symptomatic or not),confirmed COVID (any severity)

• suggested 94 % decrease in deaths
• suggested 94 % decrease in hospitalization

• suggested 97 % decrease in deaths
• suggested 97 % decrease in hospitalization
• suggested 97 % decrease in symptomatic Covid-19

• suggested 89 % decrease in infection (PCR positive symptomatic or not),confirmed COVID (any severity)

• suggested 52 % decrease in symptomatic Covid-19 but with a low degree of certainty due to high risk of bias

• statistically significant 36 % increase in Bell's palsy

• suggested 73 % decrease in confirmed COVID (any severity)
• suggested 91 % decrease in confirmed COVID (any severity)
• suggested 90 % decrease in hospitalization

• suggested 49 % decrease in symptomatic Covid-19,confirmed COVID (any severity)

• suggested 70 % decrease in hospitalization
• suggested 50 % decrease in symptomatic Covid-19,confirmed COVID (any severity)

• suggested 84 % decrease in hospitalization,severe COVID-19 occurrence but with a low degree of certainty due to high risk of bias

• statistically significant 1.4-fold increase in Bell's palsy but with a very low degree of certainty due to critical risk of bias